chevron_leftBack
As of 24 April 2025, Sandoz Group AG has a market cap of $16.8B USD, ranking #1097 globally and #30 in Switzerland. It ranks #94 in the Healthcare sector, and #9 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$16.8BUSD
13.94B CHF
Enterprise Value
$20.81BUSD
17.27B CHF
Revenue (TTM)
$11.34BUSD
9.41B CHF
EBITDA (TTM)
$801.52MUSD
665.14M CHF
EBITDA Margin
7.1%
Company Profile
Country (HQ)
Sector
Healthcare
CEO
Richard Saynor
open_in_new
Employees
22,049
Founded
1886
Website
sandoz.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 2.8% | 0.2% | -13% | -21% | -13% | 6.7% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
SDZ
Sandoz Group AG Registered Shares
ISIN: CH1243598427
Shares Out.:
Shares Outstanding:
430.7M1
Shares Float:
413.146M2
|
33.27 CHF | |
|
0SAN
Sandoz Group AG Registered Shares
ISIN: CH1243598427
|
31.89 CHF | |
|
SDZNY
Sandoz Group AG ADR
ISIN: US7999261008
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
40.03 USD | |
|
SDZXF
Sandoz Group AG Registered Shares
ISIN: CH1243598427
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
39.37 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.
